Evox Therapeutics has raised £35.5 million ($45.4 million) to support its pipeline of exosome-based drugs. The series B, which attracted the support of GV, sets Evox up to take rare disease candidates ...
OXFORD, United Kingdom, June 20, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ ...
Series C financing will also be used for the development of Evox's DeliverEX exosome drug platform Oxford-based biotech company Evox Therapeutics has completed a Series C financing round, announcing ...
Cells in the body share material via tiny vesicles that shuttle between them, carrying molecular payloads from one cell to another. Evox Therapeutics is developing medicines that leverage this ...
OXFORD, United Kingdom, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox'), a leading exosome therapeutics company, today announced a research collaboration and option agreement with the ...
Evox Therapeutics has signed a collaboration deal with Eli Lilly centred on brain/CNS disorders, which could net the latter around $1.2 billion in development, regulatory and commercial milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results